scispace - formally typeset
D

David Sammut

Researcher at University of Southampton

Publications -  13
Citations -  1217

David Sammut is an academic researcher from University of Southampton. The author has contributed to research in topics: Receptor & Interferon. The author has an hindex of 9, co-authored 11 publications receiving 1018 citations. Previous affiliations of David Sammut include Wellcome Trust & Southampton General Hospital.

Papers
More filters
Journal ArticleDOI

Defective epithelial barrier function in asthma.

TL;DR: The results show that the bronchial epithelial barrier in asthma is compromised, which may facilitate the passage of allergens and other agents into the airway tissue, leading to immune activation and may thus contribute to the end organ expression of asthma.
Journal ArticleDOI

Invariant Natural Killer T Cells in Asthma and Chronic Obstructive Pulmonary Disease

TL;DR: Investigating the frequency of invariant natural killer T cells in the airways of subjects with mild or moderately severe asthma and whether an increased number of these cells is a feature of chronic obstructive pulmonary disease (COPD) found them in low numbers.
Journal ArticleDOI

Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-beta in bronchial epithelial cells from donors with asthma.

TL;DR: BECs from subjects with asthma are biased towards higher TSLP and lower IFNβ production in response to dsRNA, suggesting that viral infection in asthma may lead to an altered mediator profile that biases towards a Th2 immune response.
Journal ArticleDOI

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, +7885 more
- 03 Mar 2022 - 
TL;DR: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials.
Journal ArticleDOI

Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cells.

TL;DR: The ADAM33 gene contains a regulatory CpG island within its promoter, the methylation status of which tightly controls its expression in a cell type-specific manner, and is a stable feature of airway epithelial cells, irrespective of disease.